AJP - Heart and Circulatory Physiology, Vol 272, Issue 2 785-H790, Copyright © 1997 by American Physiological Society

ARTICLES

beta-Adrenergic regulation of cAMP and protein phosphorylation in phospholamban-knockout mouse hearts

E. Kiss, I. Edes, Y. Sato, W. Luo, S. B. Liggett and E. G. Kranias
Department of Pharmacology, University of Cincinnati College of Medicine, Ohio 45267-0575, USA.

The stimulatory effects of beta-adrenergic agonists reflect increases in intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels and phosphorylation of key regulatory proteins in the heart. One of these phosphoproteins is phospholamban (PLB) in sarcoplasmic reticulum, and ablation of PLB is associated with attenuation of the contractile responses to beta-adrenergic stimulation in the mouse heart. To determine whether this attenuation of beta-stimulation is due to altered phosphorylation characteristics of the other key cardiac phosphoproteins and/or to compensatory responses occurring in the absence of PLB, PLB-knockout and wild-type hearts were perfused and their protein phosphorylation patterns examined. The beta-adrenergic receptor density, adenylyl cyclase activity, tissue cAMP levels, and the basal phosphoprotein pattern were similar between PLB-knockout and wild-type hearts. Isoproterenol perfusion resulted in similar increases in the tissue cAMP levels and the degree of phosphorylation of troponin I, C protein, and the 21-kDa microsomal protein in wild-type and PLB-knockout hearts. These findings indicate that the attenuation of isoproterenol-mediated increases in contractility of the PLB-knockout hearts is not due to alterations in the beta-adrenergic signal transduction pathway or the degree of phosphorylation of the key cardiac regulatory phosphoproteins in myofibrils and sarcolemma.

This article has been cited by other articles:

				A. A. Werdich, E. A. Lima, I. Dzhura, M. V. Singh, J. Li, M. E. Anderson, and F. J. Baudenbacher Differential effects of phospholamban and Ca2+/calmodulin-dependent kinase II on [Ca2+]i transients in cardiac myocytes at physiological stimulation frequencies Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2352 - H2362. [Abstract] [Full Text] [PDF]

				Y. Yang, W.-Z. Zhu, M.-l. Joiner, R. Zhang, C. V. Oddis, Y. Hou, J. Yang, E. E. Price, L. Gleaves, M. Eren, et al. Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3065 - H3075. [Abstract] [Full Text] [PDF]

				G. S. Pall, K. J. Johnson, and G. L. Smith Abnormal contractile activity and calcium cycling in cardiac myocytes isolated from dmpk knockout mice Physiol Genomics, April 16, 2003; 13(2): 139 - 146. [Abstract] [Full Text] [PDF]

				A. D. Eckhart and W. J. Koch Transgenic Studies of Cardiac Adrenergic Receptor Regulation J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 1 - 5. [Abstract] [Full Text] [PDF]

				E. Zvaritch, P. H. Backx, F. Jirik, Y. Kimura, S. de Leon, A. G. Schmidt, B. D. Hoit, J. W. Lester, E. G. Kranias, and D. H. MacLennan The Transgenic Expression of Highly Inhibitory Monomeric Forms of Phospholamban in Mouse Heart Impairs Cardiac Contractility J. Biol. Chem., May 12, 2000; 275(20): 14985 - 14991. [Abstract] [Full Text] [PDF]

				J. Zhai, A. G. Schmidt, B. D. Hoit, Y. Kimura, D. H. MacLennan, and E. G. Kranias Cardiac-specific Overexpression of a Superinhibitory Pentameric Phospholamban Mutant Enhances Inhibition of Cardiac Function in Vivo J. Biol. Chem., March 31, 2000; 275(14): 10538 - 10544. [Abstract] [Full Text] [PDF]

				L. Li, J. Desantiago, G. Chu, E. G. Kranias, and D. M. Bers Phosphorylation of phospholamban and troponin I in beta -adrenergic-induced acceleration of cardiac relaxation Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H769 - H779. [Abstract] [Full Text] [PDF]

				W. F. Bluhm, E. G. Kranias, W. H. Dillmann, and M. Meyer Phospholamban: a major determinant of the cardiac force-frequency relationship Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H249 - H255. [Abstract] [Full Text] [PDF]

				K. H. Desai, E. Schauble, W. Luo, E. Kranias, and D. Bernstein Phospholamban deficiency does not compromise exercise capacity Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1172 - H1177. [Abstract] [Full Text] [PDF]

				E. Mirit, A. Palmon, Y. Hasin, and M. Horowitz Heat acclimation induces changes in cardiac mechanical performance: the role of thyroid hormone Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1999; 276(2): R550 - R558. [Abstract] [Full Text] [PDF]

				G. Chu, L. Li, Y. Sato, J. M. Harrer, V. J. Kadambi, B. D. Hoit, D. M. Bers, and E. G. Kranias Pentameric Assembly of Phospholamban Facilitates Inhibition of Cardiac Function in Vivo J. Biol. Chem., December 11, 1998; 273(50): 33674 - 33680. [Abstract] [Full Text] [PDF]

				J. Huser, D. M. Bers, and L. A. Blatter Subcellular properties of [Ca2+]i transients in phospholamban-deficient mouse ventricular cells Am J Physiol Heart Circ Physiol, May 1, 1998; 274(5): H1800 - H1811. [Abstract] [Full Text] [PDF]

				W. Luo, G. Chu, Y. Sato, Z. Zhou, V. J. Kadambi, and E. G. Kranias Transgenic Approaches to Define the Functional Role of Dual Site Phospholamban Phosphorylation J. Biol. Chem., February 20, 1998; 273(8): 4734 - 4739. [Abstract] [Full Text] [PDF]

				G. Chu, J. W. Lester, K. B. Young, W. Luo, J. Zhai, and E. G. Kranias A Single Site (Ser16) Phosphorylation in Phospholamban Is Sufficient in Mediating Its Maximal Cardiac Responses to beta -Agonists J. Biol. Chem., December 1, 2000; 275(49): 38938 - 38943. [Abstract] [Full Text] [PDF]